Phathom Starts Pivotal Phase 3 Trial for As-Needed VOQUEZNA in Non-Erosive GERD
PHAT is trading near its 52-week low of $6.91 (5.6% above the low).
Summary
Phathom has begun patient screening in pHalcon-NERD-302, a registrational Phase 3 study testing VOQUEZNA 10 mg as an on-demand treatment for Non-Erosive GERD. Topline data are expected in Q1 2028. The trial builds on positive Phase 2 results and could support a label expansion for as-needed use, potentially broadening the drug's market beyond its current daily dosing indications. With VOQUEZNA already approved for heartburn relief in Non-Erosive GERD, this study targets a large patient population seeking episodic symptom control. The company's Q2 revenue grew 88% year-over-year to $74.3M, and this trial represents a key pipeline catalyst for future growth.
At the time of this announcement, PHAT was trading at $7.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $594.6M. The 52-week trading range was $6.91 to $18.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.